Halozyme Q2 FY26 GAAP net income rises 39% to USD 229.9 million; revenue increases 48% to USD 481 million
HALO•Raised 2026 outlook
Halozyme raised 2026 guidance to:
- Revenue: USD 1.84 billion to USD 1.91 billion
- Adjusted EBITDA: USD 1.23 billion to USD 1.28 billion
- Non-GAAP diluted EPS: USD 8.65 to USD 9.00
Adjusted profitability
Adjusted EBITDA increased 46% to USD 328.8 million; non-GAAP diluted EPS rose to USD 2.28.
Second-quarter results
Halozyme posted Q2 revenue up 48% year-over-year to USD 481 million, driven by royalty revenue up 50% to USD 308 million.
GAAP net income rose 39% to USD 229.9 million, lifting GAAP diluted EPS to USD 1.90; operating income climbed to USD 287.7 million.
Share repurchases and deal activity
The company repurchased for at each; it also signed year-to-date 2026.
